Natera, Inc. research snapshot
NTRA AI stock analysis reads Natera, Inc. as a fast-growing molecular diagnostics company with strong Signatera oncology adoption, a first quarter above one million processed tests, expanding reimbursement coverage, and positive cash inflow, set against a premium revenue multiple and continued GAAP losses. At the August 2, 2026 data cutoff, the latest available July 31 close was $267.76 and implied market capitalization was about $38.35 billion. Natera reports second quarter 2026 results on August 6, 2026, after this cutoff, so the Q2 print is the next major catalyst. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$267.76
Market cap
$38.35 billion
AI score
66 / 100
Rating
High-growth molecular diagnostics platform with positive momentum, still loss-making and premium-valued
Trend status
Revenue growth, reimbursement expansion, and positive cash inflow are constructive, while GAAP losses and a premium revenue multiple remain material
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Natera sells molecular testing services across oncology, organ health, and women health, with Signatera personalized ctDNA monitoring as a central growth engine. | High |
| Moat | Clinical evidence, lab operations, bioinformatics, physician workflows, payer evidence, and accumulated test data can reinforce adoption, and expanded coverage such as the finalized MolDx LCD and international approvals can widen access. | Medium |
| Management | CEO Steve Chapman’s team has scaled revenue and test volumes, raised 2026 guidance, and reached positive quarterly cash inflow, but the next test is converting scale into durable profitability without excessive dilution or spending. | Medium-high |
| Financial trend | FY2025 revenue grew 35.9% to $2.306 billion. Q1 2026 revenue grew 38.8% to $696.6 million, gross margin reached 64.7%, and Q1 positive cash inflow was about $11.8 million, while Q1 GAAP net loss was $85.1 million. | High |
| Valuation | At the latest $267.76 close, NTRA was valued at about $38.35 billion, roughly 15.3x trailing revenue. A GAAP P/E is not meaningful because the company remains loss-making. | High |
| Technical trend | August technical references were constructive, with price above the 50-day and 200-day moving averages and RSI near neutral, but price sits near a volatile 52-week-high area. | Medium |
| Risk level | Risk is high because the thesis relies on reimbursement, clinical adoption, oncology execution, test pricing, competition, litigation, and a premium revenue multiple. | High |
| AI confidence | Reported facts and calculations are well supported. Exact share-price outcomes are not reliably predictable, particularly for a high-multiple healthcare growth stock. | High data confidence |
| Investment certainty | Medium-low certainty. The operating trajectory is strong, but an investment case needs continued revenue growth, improving operating leverage, and resilient reimbursement. | Medium-low |
NTRA AI stock forecast
The NTRA AI stock forecast uses operating and valuation scenarios around the latest $267.76 close, rather than a P/E target. Natera reports a trailing GAAP loss, so a mechanical EPS multiple produces non-economic negative values and is not a useful valuation anchor. The scenario ranges below are conditional, not price promises. Natera reports second quarter 2026 results on August 6, 2026, after the August 2, 2026 cutoff.
$300 to $340
More likely if Q2 2026 results and the raised 2026 revenue guidance hold, Signatera and oncology volumes maintain strong growth, gross margin stays in the guided 64% to 66% range, cash inflow remains positive, payers broaden coverage, and investors keep a premium revenue multiple.
$235 to $290
More likely if revenue growth remains high but investors apply a lower revenue multiple while Natera continues spending on commercial expansion, clinical evidence, and research, keeping the stock near the average analyst target of about $282.86.
$175 to $215
More likely if reimbursement or average selling prices weaken, oncology adoption slows, competitors gain share, losses persist longer than expected, the August Q2 report disappoints, or the premium valuation compresses.
NTRA AI technical analysis
NTRA AI technical analysis is constructive but volatile at the August 2, 2026 cutoff. The July 31 close of $267.76 sat above the 50-day moving average near $244.72 and the 200-day moving average near $220.57, with RSI(14) near neutral at about 56. Price sits roughly 7% below the $288.04 52-week high, so confirmation around resistance still matters. Natera reports second quarter results on August 6, 2026, after this cutoff.
| Level | Value | Why it matters |
|---|---|---|
| Latest available close | $267.76 | StockAnalysis close at July 31, 2026. Markets were closed by the August 2 research cutoff. |
| Near support | $262 | The July 31 intraday low was $262.29. A sustained close below this area would weaken the near-term setup. |
| Secondary support | $248 to $252 | The July 28 and July 29 lows sat near $248.58 and $248.03. The 50-day moving average near $244.72 sits just below this zone. |
| Moving averages | $268.88 short term, $244.72 (50-day), $220.57 (200-day) | The 20-day average was about $268.88 from daily closes through July 31. StockAnalysis listed the 50-day and 200-day moving averages near $244.72 and $220.57 on August 1. |
| Resistance | $275 to $288 | The $275 to $284 July highs define the first resistance band, with the $288.04 52-week high from the July 6 print above it. |
| Momentum | Constructive, not overbought | StockAnalysis listed RSI(14) near 55.94 on August 1, with mixed daily momentum in late July. Disciplined entries matter in a volatile growth stock. |
| Volume | Monitor around the August 6 Q2 report | 20-day average volume was about 1.11 million shares. NTRA can reprice sharply around test volumes, guidance, payer decisions, clinical data, and litigation developments. |
| Volatility | Elevated | ATR(14) was about $11.49 from daily data through July 31. Use position sizing that recognizes healthcare growth-stock event risk. |
| Invalidation | Close below $262, then $248 | A break below the July 31 low and then the $248 to $252 zone with the 50-day moving average near $244.72 should trigger a review of both the chart and the operating thesis. |
NTRA AI trading strategy
The NTRA AI trading strategy is a rules-based framework for a volatile diagnostics growth stock. It is not personal advice and should be paired with live prices, filings, payer updates, the August 6, 2026 Q2 report, position sizing, and an independent review of risk.
Watch for NTRA to reclaim and hold the $275 to $288 resistance area with supportive volume, while revenue growth, gross margin, and the raised 2026 guidance remain intact.
A sustained close below $262 invalidates the near-term setup. A break below $248 should prompt a broader review of technical and fundamental assumptions.
If NTRA pulls back toward the $262 to $252 zone or the 50-day moving average near $244.72 without a change in reimbursement, clinical evidence, or guidance, compare the move with Q1 test volumes, cash-flow progress, and the August Q2 report.
Do not treat every decline as a buying opportunity. A reimbursement reversal, payer dispute, adverse legal development, weaker oncology adoption, or a disappointing Q2 print can change the setup quickly.
Track Signatera and oncology test volumes, average selling prices, gross margin, 2026 revenue guidance of $2.74 billion to $2.82 billion, cash inflow, debt, payer concentration, cash, share count, litigation, competitive diagnostics data, and the August 6 Q2 report.
Reduce confidence if revenue growth slows without operating leverage, if cash conversion weakens, or if the valuation remains elevated despite less favorable reimbursement or competitive evidence.
Investment research summary
Natera converts cell-free DNA and molecular-data capabilities into recurring diagnostic-test revenue by helping clinicians screen, monitor, and guide care across oncology, organ health, and women health.
The moat is built from clinical evidence, proprietary assays and bioinformatics, laboratory execution, physician workflow integration, payer evidence, and a growing data set. Expanded coverage such as the finalized MolDx LCD and international approvals can widen access, but rivals with better evidence, access, turnaround time, or economics can narrow the edge.
The thesis fails if coverage or pricing deteriorates, Signatera adoption disappoints, competitors win clinicians or payers, legal outcomes consume resources, growth spending prevents profitability, or dilution continues.
Management has scaled revenue and test volumes, raised 2026 guidance, and reached positive quarterly cash inflow. The key capital-allocation question is whether commercial and clinical investment translates into durable margins and lower dependence on share issuance.
Molecular diagnostics and liquid-biopsy monitoring can benefit from more personalized care, wider genomic-data use, and reimbursement expansion. The opportunity depends on clinical utility, regulatory standards, physician adoption, payer reimbursement, and competition.
NTRA trades at a premium revenue valuation despite GAAP losses. Margin of safety improves if guidance, margin expansion, and cash generation translate into durable profitability, and narrows if those operating assumptions weaken.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| NTRA price | $267.76 at July 31, 2026 close | StockAnalysis market overview | August 2, 2026 |
| Market capitalization | $38.35 billion, verified as $267.76 x 143.22 million shares | financial_rigor.py market-cap verification and StockAnalysis | August 2, 2026 |
| TTM revenue and net loss | $2.50 billion and -$226.32 million as of March 31, 2026 | StockAnalysis financial statements | August 2, 2026 |
| FY2025 revenue | $2.306 billion, up 35.9% year over year | StockAnalysis financial statements and Natera FY2025 release | August 2, 2026 |
| FY2025 GAAP net loss | $208.16 million | StockAnalysis financial statements and Natera 2025 Form 10-K | August 2, 2026 |
| Q1 2026 revenue and gross margin | $696.6 million and 64.7%, up 38.8% and 160 basis points year over year | Natera Q1 2026 financial results | August 2, 2026 |
| Q1 2026 tests processed | 1,013,600 total tests, including 258,900 oncology tests up 54.4% year over year | Natera Q1 2026 financial results | August 2, 2026 |
| Cash and debt at March 31, 2026 | $1,087.9 million cash, cash equivalents, and restricted cash; $80.3 million debt | Natera Q1 2026 financial results | August 2, 2026 |
| 2026 revenue guidance | $2.74 billion to $2.82 billion | Natera Q1 2026 financial results | August 2, 2026 |
| Analyst consensus and price target | Buy rating, average price target of $282.86 across 22 analysts | StockAnalysis analyst forecast | August 2, 2026 |
| Next earnings date | August 6, 2026 for second quarter 2026 results | StockAnalysis overview and Natera announcement | August 2, 2026 |
This NTRA page is an informational research tool, not investment advice or a recommendation to buy or sell. Forecast ranges are scenarios based on available data and may be wrong if financial results, reimbursement, clinical evidence, regulation, competition, litigation, interest rates, or market sentiment change. Natera reports second quarter 2026 results on August 6, 2026, after this data cutoff.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
